Omniose

About Omniose

Omniose is an early-stage biotechnology company focused on developing polysaccharide conjugate vaccines against serious bacterial threats using its proprietary bioconjugation platform. The company aims to expand the range of bacterial targets addressable by bioconjugate vaccines through a simpler and higher-quality process compared to conventional methods.

Products & Services

Polysaccharide Conjugate Vaccines:Vaccines developed using a proprietary bioconjugation platform that enables precise enzymatic attachment of bacterial polysaccharide antigens to carrier proteins within a single E. coli cell, targeting multiple bacterial threats including Group B Streptococcus, Klebsiella pneumoniae, and Streptococcus pneumoniae.

Specialties

Bioconjugation Technology Polysaccharide Conjugate Vaccines Bacterial Threat Vaccines Microbial Glycobiology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 3000000 MR: - FA: up to $3.0 million FAN: 3000000	D: 2023-09-27 FD: 2023-09-27	1 investors

Grant Latest

2023-09-27

$3.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mario Feldman

Co-Founder & Scientific Advisory Board Member

C

Christian Harding

Chief Scientific Officer

T

Timothy Cooke

Chief Executive Officer

M

Mark T. Esser

Vice President, Early Vaccines & Immune Therapies R&D

C

Christine Szymanski

Co-Founder

S

Steven Projan

Scientific Advisory Board Member

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

Omniose Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised